Phase 2 N=20 Treatment

Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars

Acne Scars

Bottom Line

View on ClinicalTrials.gov: NCT01213199 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2015

Primary outcome: Primary: Global Scarring Severity — 2.7 units on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Adapalene (Drug)
Age: Adult · 18+ yrs
Sex: All
Sponsor: Galderma R&D
Primary completion: Apr 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Global Scarring Severity	2.7	—

Summary

The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.

Eligibility Criteria

Inclusion Criteria

Male or female subjects of any race, aged 18 to 50 years inclusive
Subjects with a past history of acne and with moderate to severe facial atrophic acne scars

Exclusion Criteria

Subjects with active inflammatory acne lesions
Subjects with hypertrophic acne scars

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01213199). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.